Physician profile

Joel S Saal

Pain Medicine (Physical Medicine & Rehabilitation) · Redwood City, CA

NPI 1669430104

$4,900.18

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$23.64

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Spr Therapeutics, INC $3,254.01 2021-2023 Sprint Pns System
Vertiflex, INC. $884.73 2019
Stimwave Technologies Incorporated $593.80 2022
Assertio Therapeutics, INC. $51.06 2019
Boston Scientific Corporation $48.99 2021
Relievant Medsystems, INC. $37.25 2019
Nalu Medical, INC. $17.12 2021
Abbott Laboratories $13.22 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Joel S Saal

$4,900.18

in general payments reported 2019-2025

Years
2019-2023
Top company
Spr Therapeutics, INC

https://glasscript.com/doctor/780835/joel-s-saal

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.